UK-based gene and cell therapy group Oxford Biomedica has become part of a consortium focussed on the development, scale-up and production of a Covid-19 coronavirus vaccine candidate.
Led by Jenner Institute, University of Oxford, the consortium involves the Vaccines Manufacturing and Innovation Centre (VMIC), Cobra Biologics, Pall Life Sciences and Halix.
Vaccine ChAdOx1 nCov-19, studied in a trial in the UK, will assess vaccine candidate’s safety and ability to induce an immune response against the novel coronavirus.
Based on ChAdOx1 adenoviral vector technology developed at the Jenner Institute, the vaccine candidate was able to induce a strong immune response from one dose in preclinical and clinical trials to date.